ABBV shares trade sideways with resistance at $266.94 amid overbought technical indicators: weekly forecast

Traders Union
All News
Financial News
AbbVie slips 0.92% this week

Highlights

AbbVie sustains a strong bullish technical structure, trading well above major moving averages and resisting deeper pullbacks.
Momentum signals remain mixed with trend strength limited and several oscillators flashing overbought conditions after a recent rally.
Expected weekly range is $252.93–$266.94 with a neutral bias, as price consolidates near record highs amid balanced upside and downside probability.

Mixed sentiment as earnings adjustment and drug approval drive flows

AbbVie revised its full-year 2026 adjusted diluted earnings per share guidance to a range of $13.91 to $14.11 on July 6, 2026, citing a second-quarter EPS impact of $0.17 per share due to a pre-tax expense of $291 million related to acquired in-process R&D and milestone payments. In addition, the European Commission granted marketing authorization for TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab for the treatment of relapsed or refractory follicular lymphoma in adults. Institutional investors reported increased holdings in the first quarter.

Consolidation risk as technicals flag overbought conditions despite bullish bias

On the weekly chart, AbbVie is firmly trading above the MA-20, MA-50, and MA-200, supporting a sustained uptrend and confirming strong medium- and long-term momentum. Weekly support is seen near $252.93, with resistance at $266.94, defining the current range for price action. The weekly RSI and CCI are at or near overbought levels, and the Stochastic RSI is also in overbought territory, reflecting stretched conditions, while the ADX at 15.54 signals weak trend strength. Bull/Bear Power and the Awesome Oscillator remain supportive of the prevailing bullish tone, even as price consolidates after recent gains.

Sideways outlook next week as momentum splits and breakout risks emerge

For the next 5 trading days, AbbVie is expected to trade sideways within the $252.93 – $266.94 range, as mixed momentum signals and overbought readings favor consolidation near current levels. If bullish momentum resumes, a decisive break above $266.94 could drive the stock to fresh highs. Alternatively, a drop below $252.93 would point to a short-term correction amid overextended weekly oscillators. Probability of upward or downward movement is balanced, with 2 out of 4 weekly indicators signaling a buy.

Parshwa Turakhiya, analyst, notes that AbbVie ended this week in a strong bullish posture above all key weekly moving averages, despite the slight pullback of 0.92%. He sees institutional inflows and recent regulatory approvals as supporting sentiment, though stretched technicals and overbought signals suggest risk of a nearby pause. The balance of momentum indicators implies consolidation within the $252.93 – $266.94 range, as both upward and downward scenarios remain in play. In his view, the market is waiting for confirmation — either a new breakout or the start of a short-term correction. "With sentiment robust but momentum mixed, I’m watching the $252.93 and $266.94 levels closely for the next weekly move — not chasing, just positioning for the next break."

Earlier, analysts noted that AbbVie's bullish momentum was underpinned by strategic acquisitions and ongoing R&D progress. The current consolidation, coupled with fresh regulatory and earnings updates, signals a continuation of the uptrend, making a sustained move above $266.94 a potential catalyst for renewed gains.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.